BACKGROUND: The ability of the Essential Tremor (ET) Rating Assessment Scale (TETRAS) to detect changes in tremor severity is unknown. METHODS: Fifteen adult ET patients received a single oral ethanol dose calculated to reach 0.05 g/dL breath alcohol content (brAC). Effects were investigated independently with accelerometry and TETRAS. RESULTS: Accelerometry data were log-transformed and a cumulative score logACC(R+L) was calculated. Correlation between logACC(R+L) and TETRAS was significant. TETRAS and accelerometry showed a significant effect of time point using repeated-measures analysis of variance. The difference between baseline and each of the following six time points as well as the correlation of TETRAS with brAC were significant. The calculated minimum detectable change of TETRAS was 8.9% and the effect size was d = 4.75 (95% confidence interval: 3.60-5.90). CONCLUSION: We demonstrated sensitivity to change of the TETRAS performance scale after a therapeutic intervention, which further establishes its potential for use in both clinical and research settings.
BACKGROUND: The ability of the Essential Tremor (ET) Rating Assessment Scale (TETRAS) to detect changes in tremor severity is unknown. METHODS: Fifteen adult ET patients received a single oral ethanol dose calculated to reach 0.05 g/dL breath alcohol content (brAC). Effects were investigated independently with accelerometry and TETRAS. RESULTS: Accelerometry data were log-transformed and a cumulative score logACC(R+L) was calculated. Correlation between logACC(R+L) and TETRAS was significant. TETRAS and accelerometry showed a significant effect of time point using repeated-measures analysis of variance. The difference between baseline and each of the following six time points as well as the correlation of TETRAS with brAC were significant. The calculated minimum detectable change of TETRAS was 8.9% and the effect size was d = 4.75 (95% confidence interval: 3.60-5.90). CONCLUSION: We demonstrated sensitivity to change of the TETRAS performance scale after a therapeutic intervention, which further establishes its potential for use in both clinical and research settings.
Authors: Dietrich Haubenberger; Daniel Kalowitz; Fatta B Nahab; Camilo Toro; Dominic Ippolito; David A Luckenbaugh; Loretta Wittevrongel; Mark Hallett Journal: Mov Disord Date: 2011-06-28 Impact factor: 10.338
Authors: Giovanni Mostile; Joseph P Giuffrida; Octavian R Adam; Anthony Davidson; Joseph Jankovic Journal: Mov Disord Date: 2010-09-15 Impact factor: 10.338
Authors: Rodger J Elble; Seth L Pullman; Joseph Y Matsumoto; Jan Raethjen; Günther Deuschl; Ron Tintner Journal: Brain Date: 2006-08-03 Impact factor: 13.501
Authors: Kirsten E Zeuner; Fiona M Molloy; Richard O Shoge; Susanne R Goldstein; Robert Wesley; Mark Hallett Journal: Mov Disord Date: 2003-11 Impact factor: 10.338
Authors: Dietrich Haubenberger; Giovanni Abbruzzese; Peter G Bain; Nin Bajaj; Julián Benito-León; Kailash P Bhatia; Günther Deuschl; Maria João Forjaz; Mark Hallett; Elan D Louis; Kelly E Lyons; Tiago A Mestre; Jan Raethjen; Maria Stamelou; Eng-King Tan; Claudia M Testa; Rodger J Elble Journal: Mov Disord Date: 2016-06-06 Impact factor: 10.338
Authors: Franziska Hopfner; Dietrich Haubenberger; Wendy R Galpern; Katrina Gwinn; Ashlee Van't Veer; Samantha White; Kailash Bhatia; Charles H Adler; David Eidelberg; William Ondo; Glenn T Stebbins; Caroline M Tanner; Rick C Helmich; Fred A Lenz; Roy V Sillitoe; David Vaillancourt; Jerrold L Vitek; Elan D Louis; Holly A Shill; Matthew P Frosch; Tatiana Foroud; Gregor Kuhlenbäumer; Andrew Singleton; Claudia M Testa; Mark Hallett; Rodger Elble; Günther Deuschl Journal: Parkinsonism Relat Disord Date: 2016-10-04 Impact factor: 4.891
Authors: Tibor Zajki-Zechmeister; Mariella Kögl; Kerstin Kalsberger; Sebastian Franthal; Nina Homayoon; Petra Katschnig-Winter; Karoline Wenzel; László Zajki-Zechmeister; Petra Schwingenschuh Journal: Heliyon Date: 2020-08-19
Authors: Carmen Rodríguez-Blázquez; Maria João Forjaz; Monica M Kurtis; Roberta Balestrino; Pablo Martinez-Martin Journal: Front Neurol Date: 2018-06-07 Impact factor: 4.003